Cargando…

Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae

Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Infection is linked to high morbidity and mortality rates and antibiotic resistance within this pathogen is on the rise. Therefore, there is a need for novel antimicrobial therapies. To lower the time and costs of the drug discove...

Descripción completa

Detalles Bibliográficos
Autores principales: Cools, Freya, Torfs, Eveline, Aizawa, Juliana, Vanhoutte, Bieke, Maes, Louis, Caljon, Guy, Delputte, Peter, Cappoen, Davie, Cos, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394149/
https://www.ncbi.nlm.nih.gov/pubmed/30846978
http://dx.doi.org/10.3389/fmicb.2019.00311
_version_ 1783398834220564480
author Cools, Freya
Torfs, Eveline
Aizawa, Juliana
Vanhoutte, Bieke
Maes, Louis
Caljon, Guy
Delputte, Peter
Cappoen, Davie
Cos, Paul
author_facet Cools, Freya
Torfs, Eveline
Aizawa, Juliana
Vanhoutte, Bieke
Maes, Louis
Caljon, Guy
Delputte, Peter
Cappoen, Davie
Cos, Paul
author_sort Cools, Freya
collection PubMed
description Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Infection is linked to high morbidity and mortality rates and antibiotic resistance within this pathogen is on the rise. Therefore, there is a need for novel antimicrobial therapies. To lower the time and costs of the drug discovery process, alternative in vivo models should be considered. As such, Galleria mellonella larvae can be of great value. The larval immunity consisting of several types of haemocytes is remarkably similar to the human innate immune system. Furthermore, these larvae don’t require specific housing, are cheap and are easy to handle. In this study, the use of a G. mellonella infection model to study early pneumococcal infections and treatment is proposed. Firstly, the fitness of this model to study pneumococcal virulence factors is confirmed using streptococcal strains TIGR4, ATCC(®)49619, D39 and its capsule-deficient counterpart R6 at different inoculum sizes. The streptococcal polysaccharide capsule is considered the most important virulence factor without which streptococci are unable to sustain an in vivo infection. Kaplan–Meier survival curves showed indeed a higher larval survival after infection with streptococcal strain R6 compared to strain D39. Then, the infection was characterized by determining the number of haemocytes, production of oxygen free radicals and bacterial burden at several time points during the course of infection. Lastly, treatment of infected larvae with the standard antibiotics amoxicillin and moxifloxacin was evaluated. Treatment has proven to have a positive outcome on the course of infection, depending on the administered dosage. These data imply that G. mellonella larvae can be used to evaluate antimicrobial therapies against S. pneumoniae, apart from using the larval model to study streptococcal properties. The in-depth knowledge acquired regarding this model, makes it more suitable for use in future research.
format Online
Article
Text
id pubmed-6394149
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63941492019-03-07 Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae Cools, Freya Torfs, Eveline Aizawa, Juliana Vanhoutte, Bieke Maes, Louis Caljon, Guy Delputte, Peter Cappoen, Davie Cos, Paul Front Microbiol Microbiology Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Infection is linked to high morbidity and mortality rates and antibiotic resistance within this pathogen is on the rise. Therefore, there is a need for novel antimicrobial therapies. To lower the time and costs of the drug discovery process, alternative in vivo models should be considered. As such, Galleria mellonella larvae can be of great value. The larval immunity consisting of several types of haemocytes is remarkably similar to the human innate immune system. Furthermore, these larvae don’t require specific housing, are cheap and are easy to handle. In this study, the use of a G. mellonella infection model to study early pneumococcal infections and treatment is proposed. Firstly, the fitness of this model to study pneumococcal virulence factors is confirmed using streptococcal strains TIGR4, ATCC(®)49619, D39 and its capsule-deficient counterpart R6 at different inoculum sizes. The streptococcal polysaccharide capsule is considered the most important virulence factor without which streptococci are unable to sustain an in vivo infection. Kaplan–Meier survival curves showed indeed a higher larval survival after infection with streptococcal strain R6 compared to strain D39. Then, the infection was characterized by determining the number of haemocytes, production of oxygen free radicals and bacterial burden at several time points during the course of infection. Lastly, treatment of infected larvae with the standard antibiotics amoxicillin and moxifloxacin was evaluated. Treatment has proven to have a positive outcome on the course of infection, depending on the administered dosage. These data imply that G. mellonella larvae can be used to evaluate antimicrobial therapies against S. pneumoniae, apart from using the larval model to study streptococcal properties. The in-depth knowledge acquired regarding this model, makes it more suitable for use in future research. Frontiers Media S.A. 2019-02-21 /pmc/articles/PMC6394149/ /pubmed/30846978 http://dx.doi.org/10.3389/fmicb.2019.00311 Text en Copyright © 2019 Cools, Torfs, Aizawa, Vanhoutte, Maes, Caljon, Delputte, Cappoen and Cos. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Cools, Freya
Torfs, Eveline
Aizawa, Juliana
Vanhoutte, Bieke
Maes, Louis
Caljon, Guy
Delputte, Peter
Cappoen, Davie
Cos, Paul
Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae
title Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae
title_full Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae
title_fullStr Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae
title_full_unstemmed Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae
title_short Optimization and Characterization of a Galleria mellonella Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics Against Streptococcus pneumoniae
title_sort optimization and characterization of a galleria mellonella larval infection model for virulence studies and the evaluation of therapeutics against streptococcus pneumoniae
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394149/
https://www.ncbi.nlm.nih.gov/pubmed/30846978
http://dx.doi.org/10.3389/fmicb.2019.00311
work_keys_str_mv AT coolsfreya optimizationandcharacterizationofagalleriamellonellalarvalinfectionmodelforvirulencestudiesandtheevaluationoftherapeuticsagainststreptococcuspneumoniae
AT torfseveline optimizationandcharacterizationofagalleriamellonellalarvalinfectionmodelforvirulencestudiesandtheevaluationoftherapeuticsagainststreptococcuspneumoniae
AT aizawajuliana optimizationandcharacterizationofagalleriamellonellalarvalinfectionmodelforvirulencestudiesandtheevaluationoftherapeuticsagainststreptococcuspneumoniae
AT vanhouttebieke optimizationandcharacterizationofagalleriamellonellalarvalinfectionmodelforvirulencestudiesandtheevaluationoftherapeuticsagainststreptococcuspneumoniae
AT maeslouis optimizationandcharacterizationofagalleriamellonellalarvalinfectionmodelforvirulencestudiesandtheevaluationoftherapeuticsagainststreptococcuspneumoniae
AT caljonguy optimizationandcharacterizationofagalleriamellonellalarvalinfectionmodelforvirulencestudiesandtheevaluationoftherapeuticsagainststreptococcuspneumoniae
AT delputtepeter optimizationandcharacterizationofagalleriamellonellalarvalinfectionmodelforvirulencestudiesandtheevaluationoftherapeuticsagainststreptococcuspneumoniae
AT cappoendavie optimizationandcharacterizationofagalleriamellonellalarvalinfectionmodelforvirulencestudiesandtheevaluationoftherapeuticsagainststreptococcuspneumoniae
AT cospaul optimizationandcharacterizationofagalleriamellonellalarvalinfectionmodelforvirulencestudiesandtheevaluationoftherapeuticsagainststreptococcuspneumoniae